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Mycosis fungoides (MF) and Sezary syndrome (SS) are 
uncommon neoplasms of the lymphoreticular system 
with distinct clinical, histologic, and immunologic fea~ 
tures. Based on the thymus~derived nature of the neo~ 
plastic cells, MF and SS are both classified as cutaneous 
T~cell lymphoma. While substantially greater under~ 
standing of MF and SS has been made possible, the exact 
mechanism for the initiation of either disease is still 
unknown. The possible involvement of environmental 
factors as well as viral etiology, i.e., retroviruses, has 
been suggested. In order to investigate the possible role 
of HLA-associated variations in genetic susceptibility, 
74 patients with histologically documented MF were 
typed for HLA-A, -B, and -C antigens. Half of these 
patients were also typed for HLA-DR antigens. An in-
crease in DR5 was the only statistically significant de-
viation in HLA antigen frequencies in these patients 
(53% in MF as compared with 20% in controls). An in-
creased frequency of HLA-DR5 has also been associated 
with scleroderma and juvenile rheumatoid arthritis both 
of which have immunologic alterations. Also HLA-DR5 
has been associated with renal cell carcinoma and Ka-
posi's sarcoma. The association ofMF with DR5 suggests 
that some individuals with the DR5 antigen may be at 
higher risk for virally initiated and/or neoplastic dis-
eases possibly through an HLA-linked defect in the im-
mune system. 
Mycosis fungoides (MF) is an uncommon neoplasm of the 
lymphoreticular system with clinical, histologic, and immuno-
logic features distinct from other forms of lymphoma. Substan-
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tially greater understanding of MF and Sezru·y syndrome (SS) 
was made possible by the recent advances in the area of 
lymphocyte biology which have permitted accurate chru·acter-
ization of the neoplastic cells of MF and SS as helper type T 
lymphocyte, thus allowing classification of these disorders as 
cutaneous T-celllymphoma (CTCL) [1]. The classical form of 
the disease manifests initially in the skin and pmsues a slowly 
progressive course with eventual involvement of the internal 
organs resulting in the death of the patient. While the cause of 
CTCL remains unclear, several investigators have suggested a 
role for various environmental factors in the pathogenesis of 
the disease. Industrial exposure has been linked to the disease 
at a statistically significant level by Cohen [2]. Further, Fisch-
mann et al, found that 91% of MF patients had had multiple 
exposure to potentially cru·cinogenic chemicals [3]. R ecently 
Poiesz et al, implicated viral infection as another possible 
contributory factor by their finding of type C retrovirus parti-
cles in the cultmed lymphocytes of MF patients [ 4]. 
Aside from the environmental factors and the possible role of 
retroviruses, a genetic susceptibility has also been suggested as 
playing a part in the pathogenesis of MF. While no character-
izable mode of inheritance or ethnic group predisposition has 
been observed in the disease, an increased frequency of fiTst 
degree relatives with lymphoma and leukemia has been noted 
by some authors [5]. CTCL has been reported to occm in a 
cluster pattern in some families [6]. In addition, prior studies 
have suggested an increased occurrence ofHLA antigens (Awl9, 
BB, Cw) in MF patients [7]. These observations have led us to 
further investigate the role of genetic factors as determined by 
HLA typing in the disease. Ow- results indicate that the HLA 
genetic mru·ker DR5 is significantly increased in patients with 
MF and suggest that HLA-linked genetic susceptibility factors 
may play a role in the initiation of the disease. 
MATERIALS AND METHODS 
Seventy-four Caucasian patients with histologically documented MF, 
followed since January 1977, were included in the study. The patients 
were all tested during the period of initial diagnosis and treatment, 
relatively early in the course of their disease. The patients were typed 
for all well-defined HLA-A, -B, and -C locus antigens using a large 
battery of highly selected typing sera in the standard 2-stage lympho-
cytotoxicity test. Thirty-four of the MF patients were also typed for 
DR alloantigens using the nylon column procedure [8] for emichment 
of B cells and the modified 2-stage cytotoxicity test with prolonged 
incubation times. 
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The HLA results for all patient groups were compa1·ed to antigen 
frequencies found among a large group of Caucasian controls in the 
metropolitan New York area who represented approximately the same 
mixtUJ'e of geographical and ethnic subtype background. A substantial 
number of excess cases of MF occur in the New York metropolitan area 
[5] and most of the patients were of local origin. The control group was 
tested in ow· laboratory dUJ'ing the same time period as the patients. 
Results were compared by the chi square analysis using Yate's correc-
tion. 
RESULTS 
Results for the HLA-A, -B, -C, and -DR locus antigen fre-
quencies for the MF patients are shown in Table I. MF patients 
showed a defmite increase in the antigen Bw35 in comparison 
with the metropolitan area controls, but this was not statisti-
cally significant. 
None of the other HLA-A, -B or -C locus antigens frequencies 
showed any marked deviations from the control values. How-
ever, a hjghly significant increase in the frequency of the antigen 
HLA-DR5 was observed in the patient group. HLA-DR5 anti-
gen was found in 52.9% of the MF patients, compared with a 
frequency of 20.5% in the control population. This increase is 
statistically significant at p < 0.001 and is still significant ( p < 
0.01) after correction for the number of DR antigens tested. 
DISCUSSION 
Data from several different earlier studies of HLA antigen 
frequencies in mycosis fungoides were summarized in the 1979 
edition of HLA and Disease Registry [9] which indicated no 
significant association of any HLA-A or HLA-B locus antigen. 
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The C locus antigen Cwl was indicated to have been signifi-
cantly increased in 2 studies (Thomsen and SvejgaaTd, and 
Zachariae and Kissmeyer-Nielsen, data received at the HLA 
and Disease Registry) [9]. Published studies by MacKie et al 
[10) and Dick et al [7] had previously reported a statistically 
significant increase in the antigen BB and in the Awl9 group 
antigens (A20, w30, w31, and w32), but only 15-19 patients were 
included in their studies and the results were evidently not 
confirmed by the studies of Thomsen and Svejgaard and Za-
chariae and Kissmeyer-Nielsen [9]. No previous studies of 
HLA-DR frequencies in MF have yet been reported. 
The present study fails to confirm any association of either 
BB, Awl9 group antigens or Cwl with this disease (Table I) . 
Since the previous findings relative to BB and Awl9 had also 
not been confirmed, those results are very likely to have been 
an artifactual result of the relatively small number of patients 
tested. In relation to our failure to confirm the increase in Cwl, 
the ranges indicated for the patients in the two studies were 4-
18% (controls= 5-6%), and it seems that the increase was not 
actually significant in either study. It is also evident from our 
own data that none of t he HLA antigens usually associated in 
Caucasians with Cw1, namely B27, Bw51, and Bw56, is in-
creased in the patient group. It is therefore highly unlikely that 
our failUTe to find excess Cw1 can result from any deficiencies 
in our Cw1 typing sera. 
The significant increase of HLA-DR5 in MF patients is an 
important observation, especially in view of the recent associ-
ation of increased HLA-DR5 in other malignancies. Since these 
patients were tested relatively early in the course of their 
disease, the increase in DRS is likely to represent an increase in 
TABLE I. HLA antigen frequencies in patients with mycosis fungo ides 
Local Caucasian Mycosis fungoid es pa- Antigens Antigens controls (388)/(J 76)" Lients (74)/(34)" 
A1 29.4% 18 (24.3%)1' B17 (w57 + w58) 
A2 40.5% 29 (39.2%) B18 
A3 20.1% 13 (17.6%) Bw21 (w49 + w50) 
A9 23.2% 25 (33.8%) Bw49 
Aw23 6.3% 8 (10.8%) Bw50 
Aw24 15.1% 18 (24.3%) Bw22 (w55 + w56) 
AlO 22.7% 17 (23.0%) B27 
Aw25 8.4% 4 (5.4%) Bw35 
Aw26 14.3% 13 (17.6%) B37 
Aw34 0.0% 0 (0.0%) B40 (w60 + w61) 
All 10.1% 10 (13.5%) Bw4J 
A28 10.1% 7 (9.5%) Bw42 
A29 7.2% 3 (4.1%) Bw47 
Aw30 5.9% 6 (8.1%) Bw48 
Aw31 4.4% 3 (4.1%) Bw53 
Aw32 5.4% 6 (8.1%) Bw54 
Aw33 1.5% 5 (6.8%) B5 (w51 + w52) 
Aw36 0.0% 1 (1.4%) B7 
B8 15.5% 7 (9.5%) Cw5 
Bl2 (w44 + w45) 20.9% 15 (20.3%) Cw6 
Bw44 19.0% 15 (20.3%) 
Bw45 0.1% 0 (0.0%) DRJ. 
Bl3 7.0% 2 (2.7%) DH2 
B14 12.1% 12 (16.2%) DH3 
B15 (w62 + w63) 8.0% 11 (14.9%) DHA 
Bw62 5.5% 8 (10.8%) DH5 
Bw63 "2.1% 2 (2.7%) DHw6 
Bw16 (w38 + w39} 16.0% 14 (18.9%} DR7 
Bw38 12.4% 10 (13.5%) DHw8 
Bw39 3.6% 4 (5.4 %) DRw9 
DHwlO 
Cw1 4.9% 3 (4.1%) 
Cw2 5.9% 7 (9.5%) 
Cw3 16.0% 11 (14.9%) 
Cw4 21.9% 24 (32.4%) 
" Numbers in parentheses are those typed for HLA-A,B,C/ those typed for DR 
" Number positive for antigen (% positive for antigen). 
" DR5 is significantly increased ( p < 0.001) . 
Local Caucasian Mycosis fungoides pa-
controls (388) / ( 176) Lients (74)/(34) " 
12.1% 4 (5.4%) 
9.3% 6 (8.1%) 
7.5% 4 (5.4 %) 
6.3% 3 (4.1%) 
1.2% 1 (1.4 %) 
4.9% 4 (5.4%) 
6.4% 4 (5.4%) 
22.9% 24 (32.4%) 
2.6% 1 (1.4%) 
8.8% 9 (12.2%) 
2.1% 3 (4 .1%) 
0.0% 0 (0.0%} 
0.1% 1 (1.4%) 
0.0% 0 (0.0%) 
0.1% 1 (1.4 %) 
0.0% 0 (0.0%) 
10.8% 5 (6.8%) 
16.0% 11 (14.9%) 
9.8% 7 (9.5%) 
17.3% 5 (6.8%) 
17.6% 10 (29.4%) 
25.0% 6 (17.6%) 
21.6% 5 (14.7%) 
32.4% 8 (23.5%) 
20.5% 18 (52.9%)' 
15.3% 8 (23.5%) 
27.8% 5 (14.7%) 
1.3% 0 (0.0%) 
3.9% 1 (2.9%) 
0.0% 0 (0.0%) 
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TABLE II. Other diseases with signi(icant DR5 associations 
Disease Reference Patients Controls 
Early-onset juvenile rheu- [15] 14/22 = 64% 29/ 133 = 22% 
matoid arthritis 
Scleroderma [14] 18/ 34 = 53% 33/ 180 = 18% 
Ren al cell carcinoma [13] 14/26 =54% 25/124 = 20% 
Kaposi's sarcoma [12] 9/14 = 60% 
susceptibility rather than selective resistance (smvival). Are-
cent report indicated a similarly increased frequency of this 
antigen in young homosexual males with an aggressive form of 
Kaposi's sarcoma [11]. These findings have been confirmed in 
our laboratory [12]. In addition, we have discerned an increase 
in t h e frequency ofHLA-DR5 in patients with classical Kaposi's 
sarcoma. 
An increase in DR5 has also been reported in another form 
of cancer, renal cell carcinoma [13]. The authors speculated 
that since there is relatively frequent occmrence of spontaneous 
regression in this disease, the association with DR5 may involve 
an immunogenetic factor. Since the etiologies of both renal cell 
carcinoma and MF have also been associated with (industrial) 
exposme to toxic chemicals and irritants, it is also possible to 
speculate that the association of DR5 with both these malig-
nancies may result from a DR5-linked defect in the capacity to 
neutralize or metabolize such agents. 
Finally, some of the other HLA disease associations with 
DR5 that have been described to date include scleroderma [14] 
and the early-onset form of juvenile rheumatoid arthritis [15] 
(Table Il) . In both of these diseases, immunologic alterations 
play an important role in the pathogenesis of the disease. It is 
possible that similar (DRS-associated) immunologic alterations 
may play a role in the etiology of MF. 
The authors also wish to acknowledge the exper t technical assistance 
of Cynthia Calloway and Honoralta Peralta and the expert typing of 
Laura Asadorian. 
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